

## Descriptives

	N	Minimum	Maximum	Mean	Std. Deviation
Group	201	1	2	1.50	.501
Sex	201	1	2	1.62	.486
Age	201	18	45	32.38	7.139
Duration_0	201	4	49	22.97	14.402
Duration_1.5	201	1	22	10.04	2.617
Duration_3	201	1	9	4.12	2.128
Frequency_0	201	3	16	10.00	4.036
Frequency_1.5	201	3	10	6.40	1.603
Frequency_3	201	1	3	1.89	.786
VAS_0	201	25	98	72.60	18.292
VAS_1.5	201	15	40	31.46	7.273
VAS_3	201	5	30	19.71	6.164
B6_0	201	1	5	4.17	1.049
B6_1.5	201	1	4	2.77	1.023
B6_3	201	1	2	1.41	.494
Valid N (listwise)	201				

## Frequencies

		Statistics											
		Duration_0	Duration_1.5	Duration_3	Frequency_0	Frequency_1.5	Frequency_3	VAS_0	VAS_1.5	VAS_3	B6_0	B6_1.5	B6_3
N	Valid	201	201	201	201	201	201	201	201	201	201	201	201
	Missing	0	0	0	0	0	0	0	0	0	0	0	0
Mode		49	12	2	16	5	2	81	37	21	5	3	1

## NPar Tests

		One-Sample Kolmogorov-Smirnov Test											
		Age	Duration_0	Duration_1.5	Duration_3	Frequency_0	Frequency_1.5	Frequency_3	VAS_0	VAS_1.5	VAS_3		
N		201	201	201	201	201	201	201	201	201	201	201	201
Normal Parameters <sup>a,b</sup>	Mean	32.38	22.97	10.04	4.12	10.00	6.40	1.89	72.60	31.46	19.71		
	Std. Deviation	7.139	14.402	2.617	2.128	4.036	1.603	.786	18.292	7.273	6.164		
Most Extreme Differences	Absolute	.057	.126	.175	.139	.091	.142	.240	.160	.176	.122		
	Positive	.054	.126	.122	.139	.090	.142	.240	.090	.120	.082		
	Negative	-.057	-.094	-.175	-.109	-.091	-.135	-.187	-.160	-.176	-.122		
Test Statistic		.057	.126	.175	.139	.091	.142	.240	.160	.176	.122		
Asymp. Sig. (2-tailed)		.200 <sup>c,d</sup>	.000 <sup>c</sup>	.000 <sup>c</sup>	.000 <sup>c</sup>	.000 <sup>c</sup>	.000 <sup>c</sup>	.000 <sup>c</sup>	.000 <sup>c</sup>	.000 <sup>c</sup>	.000 <sup>c</sup>		

a. Test distribution is Normal.

b. Calculated from data.

c. Lilliefors Significance Correction.

d. This is a lower bound of the true significance.

## T-Test

### Group Statistics

	Group	N	Mean	Std. Deviation	Std. Error Mean
Age	Venlafaxine	100	32.32	7.290	.729
	Nortriptyline	101	32.44	7.022	.699

### Independent Samples Test

		Levene's Test for Equality of Variances					t-test for Equality of Means		95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Age	Equal variances assumed	.174	.677	-.115	199	.909	-.116	1.010	-2.107	1.875
	Equal variances not assumed			-.115	198.552	.909	-.116	1.010	-2.107	1.876

## T-Test

### Group Statistics

	Sex	N	Mean	Std. Deviation	Std. Error Mean
Age	Male	76	32.20	6.611	.758
	Female	125	32.49	7.466	.668

### Independent Samples Test

		Levene's Test for Equality of Variances					t-test for Equality of Means		95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper

Age	Equal variances assumed	1.222	.270	-.279	199	.780	-.291	1.041	-2.343	1.762
	Equal variances not assumed			-.288	173.354	.774	-.291	1.010	-2.285	1.704

## NPar Tests

### Mann-Whitney Test

		Ranks		
	Group	N	Mean Rank	Sum of Ranks
Duration_0	Venlafaxine	100	98.32	9831.50
	Nortriptyline	101	103.66	10469.50
	Total	201		
Duration_1.5	Venlafaxine	100	97.11	9710.50
	Nortriptyline	101	104.86	10590.50
	Total	201		
Duration_3	Venlafaxine	100	93.27	9327.00
	Nortriptyline	101	108.65	10974.00
	Total	201		
Frequency_0	Venlafaxine	100	101.23	10123.00
	Nortriptyline	101	100.77	10178.00
	Total	201		
Frequency_1.5	Venlafaxine	100	107.74	10773.50
	Nortriptyline	101	94.33	9527.50
	Total	201		
Frequency_3	Venlafaxine	100	91.18	9117.50
	Nortriptyline	101	110.73	11183.50
	Total	201		
VAS_0	Venlafaxine	100	104.41	10440.50
	Nortriptyline	101	97.63	9860.50
	Total	201		
VAS_1.5	Venlafaxine	100	105.15	10515.00
	Nortriptyline	101	96.89	9786.00
	Total	201		
VAS_3	Venlafaxine	100	100.69	10069.00
	Nortriptyline	101	101.31	10232.00

	Total	201		
B6_0	Venlafaxine	100	99.40	9939.50
	Nortriptyline	101	102.59	10361.50
	Total	201		
B6_1.5	Venlafaxine	100	97.98	9798.00
	Nortriptyline	101	103.99	10503.00
	Total	201		
B6_3	Venlafaxine	100	96.69	9668.50
	Nortriptyline	101	105.27	10632.50
	Total	201		

**Test Statistics<sup>a</sup>**

	Duration_0	Duration_1.5	Duration_3	Frequency_0	Frequency_1.5	Frequency_3	VAS_0	VAS_1.5	VAS_3	B6_0	B6_1.5	B6_3
Mann-Whitney U	4781.500	4660.500	4277.000	5027.000	4376.500	4067.500	4709.500	4635.000	5019.000	4889.500	4748.000	4618.500
Wilcoxon W	9831.500	9710.500	9327.000	10178.000	9527.500	9117.500	9860.500	9786.000	10069.000	9939.500	9798.000	9668.500
Z	-.652	-.957	-1.892	-.056	-1.659	-2.539	-.826	-1.008	-.075	-.423	-.763	-1.227
Asymp. Sig. (2-tailed)	.515	.339	.058	.955	.097	.011	.409	.313	.940	.672	.446	.220

a. Grouping Variable: Group

**NPar Tests**

**Mann-Whitney Test**

		Ranks		
	Sex	N	Mean Rank	Sum of Ranks
Duration_0	Male	76	101.85	7740.50
	Female	125	100.48	12560.50
	Total	201		
Duration_1.5	Male	76	100.84	7663.50
	Female	125	101.10	12637.50
	Total	201		
Duration_3	Male	76	103.75	7885.00
	Female	125	99.33	12416.00

	Total	201		
Frequency_0	Male	76	88.08	6694.00
	Female	125	108.86	13607.00
	Total	201		
Frequency_1.5	Male	76	98.61	7494.50
	Female	125	102.45	12806.50
	Total	201		
Frequency_3	Male	76	97.63	7420.00
	Female	125	103.05	12881.00
	Total	201		
VAS_0	Male	76	99.74	7580.50
	Female	125	101.76	12720.50
	Total	201		
VAS_1.5	Male	76	97.38	7401.00
	Female	125	103.20	12900.00
	Total	201		
VAS_3	Male	76	99.23	7541.50
	Female	125	102.08	12759.50
	Total	201		
B6_0	Male	76	95.19	7234.50
	Female	125	104.53	13066.50
	Total	201		
B6_1.5	Male	76	96.41	7327.50
	Female	125	103.79	12973.50
	Total	201		
B6_3	Male	76	105.78	8039.50
	Female	125	98.09	12261.50
	Total	201		

**Test Statistics<sup>a</sup>**

	Duration_0	Duration_1.5	Duration_3	Frequency_0	Frequency_1.5	Frequency_3	VAS_0	VAS_1.5	VAS_3	B6_0	B6_1.5	B6_3
Mann-Whitney U	4685.500	4737.500	4541.000	3768.000	4568.500	4494.000	4654.500	4475.000	4615.500	4308.500	4401.500	4386.500
Wilcoxon W	12560.500	7663.500	12416.000	6694.000	7494.500	7420.000	7580.500	7401.000	7541.500	7234.500	7327.500	12261.500
Z	-.161	-.032	-.527	-2.465	-.461	-.682	-.239	-.689	-.337	-1.199	-.907	-1.066
Asymp. Sig. (2-tailed)	.872	.975	.598	.014	.645	.495	.811	.491	.736	.230	.364	.286

a. Grouping Variable: Sex

## Frequencies

		Statistics			
		Decreased_Durati on	Decreased_Frequ ency	Decreased_VAS	Decreased_B6
N	Valid	201	201	201	201
	Missing	0	0	0	0

## Frequency Table

		Decreased_Duration			Cumulative
		Frequency	Percent	Valid Percent	Percent
Valid	50%Decreased	170	84.6	84.6	84.6
	Not Decreased	31	15.4	15.4	100.0
	Total	201	100.0	100.0	

		Decreased_Frequency			Cumulative
		Frequency	Percent	Valid Percent	Percent
Valid	50%Decreased	191	95.0	95.0	95.0
	Not Decreased	10	5.0	5.0	100.0
	Total	201	100.0	100.0	

**Decreased\_VAS**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	50%Decreased	201	100.0	100.0	100.0

**Decreased\_B6**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	50%Decreased	196	97.5	97.5	97.5
	Not Decreased	5	2.5	2.5	100.0
	Total	201	100.0	100.0	

**Crosstabs**

**Case Processing Summary**

	Valid		Cases Missing		Total	
	N	Percent	N	Percent	N	Percent
Group * Decreased_Duration	201	100.0%	0	0.0%	201	100.0%
Group * Decreased_Frequency	201	100.0%	0	0.0%	201	100.0%
Group * Decreased_VAS	201	100.0%	0	0.0%	201	100.0%
Group * Decreased_B6	201	100.0%	0	0.0%	201	100.0%



## Group \* Decreased\_Duration

### Crosstab

Count

		Decreased_Duration		Total
		50%Decreased	Not Decreased	
Group	Venlafaxine	81	19	100
	Nortriptyline	89	12	101
Total		170	31	201

### Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	1.952 <sup>a</sup>	1	.162		
Continuity Correction <sup>b</sup>	1.445	1	.229		
Likelihood Ratio	1.966	1	.161		
Fisher's Exact Test				.177	.115
Linear-by-Linear Association	1.942	1	.163		
N of Valid Cases	201				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 15.42.

b. Computed only for a 2x2 table

## Group \* Decreased\_Frequency

### Crosstab

Count

		Decreased_Frequency		Total
		50%Decreased	Not Decreased	
Group	Venlafaxine	98	2	100
	Nortriptyline	93	8	101
Total		191	10	201

### Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	3.726 <sup>a</sup>	1	.054		
Continuity Correction <sup>b</sup>	2.579	1	.108		
Likelihood Ratio	3.981	1	.046		
Fisher's Exact Test				.101	.052
Linear-by-Linear Association	3.707	1	.054		
N of Valid Cases	201				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 4.98.

b. Computed only for a 2x2 table

**Group \* Decreased\_VAS**

**Crosstab**

Count

		Decreased_VAS	
		50%Decreased	Total
Group	Venlafaxine	100	100
	Nortriptyline	101	101
Total		201	201

**Chi-Square Tests**

	Value
Pearson Chi-Square	.a
N of Valid Cases	201

a. No statistics are computed because  
Decreased\_VAS is a constant.

**Group \* Decreased\_B6**

**Crosstab**

Count

		Decreased_B6		Total
		50%Decreased	Not Decreased	
Group	Venlafaxine	96	4	100
	Nortriptyline	100	1	101
Total		196	5	201

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	1.877 <sup>a</sup>	1	.171		
Continuity Correction <sup>b</sup>	.841	1	.359		
Likelihood Ratio	2.004	1	.157		
Fisher's Exact Test				.212	.181
Linear-by-Linear Association	1.867	1	.172		
N of Valid Cases	201				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 2.49.

b. Computed only for a 2x2 table